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ABSTRACT
Objective To estimate the extent of overdiagnosis (the
detection of cancers that will not cause death or
symptoms) in publicly organised screening programmes.
Design Systematic review of published trends in
incidence of breast cancer before and after the
introduction of mammography screening.
Data sources PubMed (April 2007), reference lists, and
authors.
Review methods One author extracted data on incidence
of breast cancer (includingcarcinomain situ), population
size, screening uptake, time periods, and age groups,
which were checked independently by the other author.
Linear regression was used to estimate trends in
incidence before and after the introduction of screening
and in older, previously screened women. Meta-analysis
was used to estimate the extent of overdiagnosis.
Results Incidence data covering at least seven years
before screening and seven years after screening had
beenfullyimplemented,andincludingbothscreenedand
non-screened age groups, were available from the United
Kingdom; Manitoba, Canada; New South Wales,
Australia; Sweden; and parts of Norway. The
implementation phase with its prevalence peak was
excluded and adjustment made for changingbackground
incidence and compensatory drops in incidence among
older, previously screened women. Overdiagnosis was
estimatedat52%(95%confidenceinterval46%to58%).
Data from three countries showed a drop in incidence as
the women exceeded the age limit for screening, but the
reduction was small and the estimate of overdiagnosis
was compensated for in this review.
Conclusions The increase in incidence of breast cancer
was closely related to the introduction of screening and
little of this increase was compensated for by a drop in
incidenceofbreastcancerinpreviouslyscreenedwomen.
One in three breast cancers detected in a population
offered organised screening is overdiagnosed.
INTRODUCTION
Screening for cancer may lead to earlier detection of
lethal cancers but also detects harmless ones that will
not cause death or symptoms. The detection of such
cancers, which would not have been identified clini-
cally in someone’s remaining lifetime, is called over-
diagnosis and can only be harmful to those who
experience it.
1 As it is not possible to distinguish
between lethal and harmless cancers, all detected can-
cers are treated. Overdiagnosis and overtreatment are
therefore inevitable.
2
It iswell knownthatmanycasesofcarcinomain situ
inthebreastdonotdevelopintopotentiallylethalinva-
sivedisease.
1Incontrast,manyfinditdifficulttoaccept
that screening for breast cancer also leads to overdiag-
nosis of invasive cancer. Harmless invasive cancer is
common, however, even for lung cancer, with 30%
overdiagnosis after long term follow-up of patients
screened by radiography.
2 Autopsy studies have
shown that invasive prostate cancer occurs in about
60% of men in their 60s, whereas the lifetime risk of
dying from such cancer is only about 3%.
2 Autopsy
studies have also found inconsequential breast cancer
lesions. Thirty seven per cent of women aged 40-54
who died from causes other than breast cancer had
lesions of invasive or non-invasive cancer at autopsy,
and half were visible on radiography.
34
Overdiagnosis can be measured precisely in a ran-
domised trial with lifelong follow-up if people are
assigned to a screening or control group for as long as
screening would be offered in practice, which in most
countries is 20 years. Overdiagnosis would be the dif-
ference in number of cancers detected during the life-
time of the two groups, provided the control group or
age groups not targeted are not screened. In the
absence of overdiagnosisthe initial increase in cancers
inthescreenedagegroupswouldbefullycompensated
for by a similar decrease in cancers among older age
groups no longer offered screening, as these cancers
would already have been detected.
The extent of overdiagnosis and overtreatment as a
result of mammography screening was first quantified
in reviews of randomised trials.
56The total number of
mastectomies and lumpectomies increased by 31%
and mastectomies by 20%.
6 As these trials did not
have lifelong follow-up the extent of overdiagnosis
could have been overestimated. Underestimation is
also possible, however, as the randomised design was
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6 and as opportunistic
screening occurred in the control groups.
7
Screening programmes differ from randomised
trials. Radiologists outside a rigorous trial setting may
belesswelltrainedthanthoseinthetrial,andtechnical
developments resulting in higher resolution images
may also affect outcomes. The basic premise of an
unchangedlifetimeriskofbreastcancerintheabsence
of overdiagnosis is, however, the same.
To estimatetheextentof overdiagnosisin organised
screening programmes we compared trends in breast
cancer incidence before and after screening, taking
account of changes in the background incidence and
any compensatory drop in incidence of breast cancer
among older, previously screened women. We com-
bined our results in a meta-analysis.
METHODS
We included articles in any language with data on
breast cancer incidence for both screened and older,
non-screenedagegroupsforatleastsevenyearsbefore
screening and seven years after screening had been
fully implemented, regardless of the time it took to
implement screening. We reasoned that a long period
after implementation was necessary to obtain an esti-
mate of the trend in breast cancer incidence that was
unaffected by the initial peak in prevalence when
screening is introduced. Acquiring incidence data for
age groups older than those screened allowed us to
evaluate any compensatory declines in incidence
among previously screened women.
When a country was described in several papers we
selectedtheonewiththemostrecentandbestreported
data as our core article, and we supplemented with
other papers when relevant. When possible we also
added data from the internet and supplied by authors.
Wedidnotsearchforarticlespublishedbefore1990,as
insufficienttimewouldhaveelapsedaftertheinitiation
of screening.
Literature searches
Our searches in PubMed were developed iteratively
and we tried several search strings. The final search,
which identified all included articles, was: ((“Mammo-
graphy”[MeSH] OR “Mass Screening”[MeSH]) AND
((“Breast Neoplasms/epidemiology”[MeSH]) OR
(“Breast Neoplasms”[MeSH] AND incidence*[ti])))
OR (Breast cancer AND screening AND trend*[ti])
OR (Breast cancer AND screening AND overdiag-
nos*[ti]).
One author scanned titles and abstracts and
retrieved the full text of potentially relevant articles
for evaluation of eligibility, scanned the reference
lists, and contacted authors. We compared the final
search with an archive of all articles on breast cancer
screening published in 2004, which we have used for
another study,
8 and found that we had not missed any
potentially relevant papers. None of the four authors
we contacted told us of additional studies but three
provided unpublished data or referred us to internet
resources.
9 We did not find additional studies in the
reference lists.
Data extraction
Bothauthorsextracteddataindependently,withdiffer-
ences resolved by discussion. We extracted data on
population size, screening uptake, length of time
before and after the implementation of screening, and
incidence of breast cancer for both screened and non-
screened age groups. If data on carcinoma in situ were
missing, we estimated overdiagnosis with these cases
included, assuming that they would contribute 10%
of the diagnoses in a population offered screening
1011
—that is, we divided the incidence of invasive cancers
by 0.9.
Selection of last prescreening year
The last prescreening year was usually the year before
formal implementation of screening. If the levels of
invasive breast cancer or carcinoma in situ appeared
to increase abruptly in the years immediately before
the introduction of screening, however, we excluded
these years from estimates of trends before screening.
Carcinoma in situ is rarely diagnosed without screen-
ingandsuchincreasesindicateopportunisticscreening
(screening outside the organised programme). Simi-
larly,abruptlyincreasedratesofinvasivebreastcancer
immediately before formal implementation of screen-
ing likely indicate pilot programmes or extensive
opportunistic screening.
Calculation of overdiagnosis in absence of compensatory
drop
We used simple linear regression to estimate trends as
we could not use Poisson regression because the
denominators for the reported rates of breast cancer
were not available. To compensate for changes in
background incidence in the screened age group we
carried out a linear regression analysis of the prescre-
eningyearsandextendedthisregressionlinetothelast
observationyear.Weusedthecalculatedvalueforthis
year to estimate what the expected incidence would
have been in the absence of screening.
We did another linear regression analysis for the
screened age group but used the observed incidence
in that part of the screening period where the pro-
gramme was fully implemented and past any preva-
lence peak. This was done to take account of annual
fluctuations. The rate ratio between the result for the
last observation year determined by linear regression
and the expected incidence in that year (that is, the
observedincidenceinthelastobservationyeardivided
by the expected incidence in the last observation year)
constituted our estimate of overdiagnosis.
Calculation of overdiagnosis in presence of compensatory
drop
In the age group that exceeded the age for screening,
we studied whether the observed increase in the
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lower than the expected increase, in both cases using
linear regression. If this was the case, we considered
thatthedifferencebetweentheobservedandexpected
incidence was due to a compensatory drop. We calcu-
latedthesizeofthisdropasarateratio,asabove,using
the last observation year.
From this rate ratio we calculated the absolute num-
berofbreastcancercasesper100000womenthatcor-
responded to the drop in the older age groups (X).
Similarly, for the screened age groups we calculated
the number of extra cases of breast cancer (those
above the expected number) per 100000 women that
correspondedtotheincrease(Y).Wecompensatedfor
the many more women in the younger, screened age
group (A) than in the older age group of previously
screened women (B) using official population statistics
to calculate a correction factor C=A/B.
Wecalculated(Y×C−X)/(Y×C),whichisthepercen-
tage of breast cancer cases uncompensated for of the
totalpercentageincreaseinincidenceamongscreened
women. Overdiagnosis was then the observed percen-
tageincreaseinincidencemultipliedbythepercentage
of uncompensated for breast cancers (see Manitoba
under Results for a numerical example).
Women too young to be screened
Ifavailablewe usedthegroupofwomenwhoweretoo
young to be screened as a control to see if our extra-
polated prescreening trend for the screened age group
was a reasonable estimate of the background inci-
dence, if screening had not been introduced. We did
alinearregressionanalysisusingtheprescreeninginci-
dence, extrapolated the trend into the screening per-
iod, as for the other age groups, and compared with
the observed incidence.
Meta-analysis
We combined the estimates using Comprehensive
Meta Analysis version 2.2.046 (random effects
model). As we estimated overdiagnosis using only the
last observation year, our estimate has wider confi-
denceintervalsthanifwehadusedseveralobservation
years. We used population sizes and age distributions
obtained from internet sources
9 or as provided by the
authors.
RESULTS
The PubMed search (May 2006) yielded 2861 titles,
2546 of which were not relevant (fig 1). The full text
oftheremaining315articleswasevaluatedforeligibil-
ity. Four were included as core articles and one was
addedwhenthesearchwasupdatedinApril2007,pre-
senting data from the United Kingdom; Manitoba,
Titles and abstracts identified through PubMed search (n=2861)
Articles retrieved as hard copy (n=315)
Accepted (n=4)
Included as core articles (n=5)
Eligible article located in updated search (n=1)
Not relevant (n=2546):
No data on breast cancer incidence,
or incidence not reported over time
Not eligible (n=311):
No screening, or only screening in some areas, with
  collectively reported data
More up to date data available elsewhere
Insufficient follow-up (<7 years)
Insufficient prescreening period (<7 years)
Insufficient reporting - for example, incidence for all
  ages reported collectively, time periods lumped
  together, no data for previously screened women
Fig 1 | Selection of core articles
Overview of individual estimates of overdiagnosis for invasive breast cancer, excluding cases of carcinoma in situ except for Manitoba, Canada
Variables United Kingdom Manitoba, Canada New South Wales, Australia Sweden Norway(AORHcounties)
Period for estimation of prescreening trend 1971-84 1970-8 1972-87 1971-85 1980-94
Selection method for last prescreening year Opportunistic screening
starts
Opportunistic screening
starts
Last year before screening Last year before
screening
Last year before
screening
Period for estimation of postscreening trend 1993-9 1995-2005 1996-2002 1998-2006 2000-6
Breast cancer incidence in final year of observation (per 100 000 women)
Screened age group:
Observed (regression analysis) 278 318/375* 291 328 303
Expected (regression analysis) 197 236/236* 211 242 213
Observed/expected 1.41 1.35/1.59 1.38 1.35 1.42
Exceeded age for screening:
Observed (regression analysis) 278 401/442* 317 303 (1998) 246
Expected (regression analysis) 277 498/522* 289 338 (1998) 289
Observed/expected 1.01 0.81/0.85 1.10 0.90 0.85
Compensatory drop No Yes No Yes Yes
Overdiagnosis (%) with CIS NA 44 NA NA NA
Estimated overdiagnosis (%), assuming 10% CIS 57 53 46 52
AORH=Akershus, Oslo, Rogaland, and Hordaland; NA=not available; CIS=carcinoma in situ.
*Without/with CIS.
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parts of Norway (table).
12-16 (See web extra for data
from an additional eight countries and reasons for
exclusion.)
United Kingdom
Screening started in the UK in 1988 for women aged
50-64, with national coverage by 1990, and was
expanded to women aged 65-70 in 2002.
17 Data from
England and Wales covered 1971-99 in graphs with
five year age groups.
12 These data were combined
andtheprescreeningperioddefinedas1971-84,before
opportunistic screening had influenced the back-
ground incidence (fig 2). The period 1993-9 was used
to estimate the most recent trend. The increase in inci-
dence of invasive cancer in women aged 50-64 was
41% above the expected rate, interpreted as overdiag-
nosis as there was no compensatory drop in the older
agegroups(fig2).Theincidenceinyoungeragegroups
(30-49 years) increased by 7% over expected rates and
in older age groups (65-74 years) by 1% over expected
rates. Nodata were available forcarcinoma in situ,but
assuming that 10% of the diagnoses in a population
offered screening are for carcinoma in situ,
1011 over-
diagnosis would be 57% (table).
More recent data (1995-2003) have been
published,
17 but only for screened age groups. Inci-
dence continues to increase.
Manitoba, Canada
NonationaldatawerefoundforCanada.InManitoba,
elective screening has been available since the late
1970s, with formal implementation in 1995 for
women aged 50-69.
13 A study compared incidence up
to 1999.
13 More recent data were received from the
author (fig 3). As the incidence of carcinoma in situ
started to increase in 1979, corresponding to the avail-
ability of elective screening, the prescreening period
was defined as 1970-8. The period 1995-2005 was
usedtoestimatethetrendafterscreening.Intheinvited
age group the incidence for invasive cancer was 35%
above the expected rate, and when carcinoma in situ
was included it was 59% higher. The total rate for the
age group 70-84 was 15% below expected, but for the
age group 35-49 it was 32% below expected, which
suggests that causes other than screening could have
contributed to the drop among previously screened
women.
Inthelastobservationyearthe59%increase(includ-
ing carcinoma in situ) in women aged 50-69 corre-
sponds to 140 extra breast cancer diagnoses per
100000 women, and the 15% decline in women aged
70-84 corresponds to80fewerbreastcancerdiagnoses
per 100000 women. In Manitoba, 2.3 times as many
women are aged 50-69 than are aged 70-84,
9 and 75%
(=(140×2.3-80)/(140×2.3)) of the increase is therefore
uncompensated. A conservative estimate of overdiag-
nosis is therefore 59%×75%=44%.
New South Wales, Australia
Nationaldataonprescreeningrateswerenotpresented
for Australia.
18 The introduction of screening varied
from state to state, and follow-up was short.
For New South Wales, where screening was intro-
duced during 1988-95, a graph showed an increase of
55% for invasive cancer over expected rates in women
aged 50-69.
14 When the prescreening period was
defined as 1972-87 and the period 1996-2002 was
used to estimate the trend after screening, this age
group showed an increase of 38% over expected rates
Exceeded age for screening (65-74 years)
Expected - no screening
Screening age (50-64 years)
Expected - no screening
Observed - with screening
Too young to be screened (30-49 years)
Expected - no screening
Year
B
r
e
a
s
t
 
c
a
n
c
e
r
 
i
n
c
i
d
e
n
c
e
 
p
e
r
 
1
0
0
 
0
0
0
 
w
o
m
e
n
0
100
150
200
250
300
Screening
introduced 1988-90
After
screening
Before
screening
50
1971
1973
1975
1977
1979
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
Fig 2 | Incidence of invasive breast cancer per 100000 women
in UK
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Fig 3 | Incidence of invasive breast cancer and carcinoma in
situ per 100000 women in Manitoba, Canada
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increase in incidence was constant (fig 4). Women
aged more than 70 were eligible but not targeted. No
compensatorydropwasobserved;theincidencewasin
factlargerthanexpected.Overdiagnosisincludingcar-
cinoma in situ was therefore estimated at 53% (table).
A similar development was seen in South Australia,
but the prescreening period was indicated as one data
point, which precluded estimation of prescreening
trends.
19
Sweden
Women in a few areas of Sweden participated in
screening trials from 1969; nationwide screening
started in 1986, and in 1998 almost all eligible
women had been offered screening.
20 For various
counties in 1999, eight different targeted age ranges
were described
20; the broadest was 40-74 years and
the most common was 50-69 years. A study reported
an increase in invasive cancer after screening of 69%
aboveexpectedratesinwomenaged50-59and27%in
women aged 60-69.
15 After adjustment for lead time,
with estimates varying from 1.6 to 3.0 years, the
increases in 2000 were 54% and 21%, respectively.
15
Another report
21 showed similar increases, without a
compensatory drop in older age groups, whereas a
third report noted a drop in incidence of 12% in those
agedmorethan75,andnochangeforwomenaged70-
74.
22
Data up to 2006 were received from one of the
authors (fig 5).
22 The meta-analysis focused on the
age group 50-69, as this is the only group offered
screeninginallregions.Usingtheprescreeningperiod
as 1971-85 and the period 1998-2006 to estimate the
trend after screening, the estimated increase for
invasive cancer over expected rates was 35%, or 86
additional breast cancers per 100000 women in the
last observation year. A constant increase in incidence
was seen among women too young to be screened
(fig 5). A drop occurred among women aged 70-84,
but incidence approached the expected rate at the
end of the observation period (fig 5). In the middle of
the interval after screening had started in 1998, 10%
fewer invasive breast cancers were detected than
expected, or 35 fewer cancers per 100000 women.
Eighty eight per cent of the increase was therefore
uncompensated.Despiteusingdatawhenthecompen-
satory decline was largest (rather than from the last
observation year), this adjustment only changed the
estimate of overdiagnosis for invasive breast cancer
from 35% to 31%. When carcinoma in situ was
included overdiagnosis was 46% (table).
Norway
Screening was introduced in Norway in 1995-6 for
women aged 50-69, but only in 40% of the population
(Akershus, Oslo, Rogaland, and Hordaland counties;
fig 6), and in the rest of Norway from 1999, gaining
national coverage in 2004 (fig 7).
16 Attendance was
good (75-77%).
1622 As screening was fully implemen-
tedintheothercountiesin2004,overdiagnosiswasnot
estimated for these areas, although the data are pre-
sentedgraphicallyforcomparison(fig7).InAkershus,
Oslo, Rogaland, and Hordaland, a peak in prevalence
forinvasivebreastcancerwasfollowedbystablelevels,
above prescreening rates in the screened age
group.
1622 Screening is generally offered to women
aged 50-69, but about 50% of those aged 70-74 were
probably screened,
23 and incidence initially increased
by 30% in this age group and then decreased to
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Fig 4 | Incidence of invasive breast cancer per 100000 women
in New South Wales, Australia
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50 and more than 74 was stable. Another study
reported similar increases but had shorter follow-
up.
22
Additional data were received from one of the
authors.
22 The age group 50-69 years was considered
as screened. The prescreening period was defined as
1980-94 and the period 2000-6 was used to estimate
the trend after screening. The increase in invasive
breast cancer was estimated as 42% above expected
rates, or 90 additional breast cancers per 100000
women in the last observation year. Among women
too young to be screened the increase in incidence
was constant, but data for this group were only avail-
able divided into counties from 1991 (fig 6). A 15%
dropwasseenamongwomenaged70-79,butasimilar
drop was also observed in the rest of Norway before
screening was fully implemented (fig 7). The drop was
conservatively considered as compensatory. The 15%
fewer invasive breast cancers correspond to 43 fewer
cancers per 100000 women. This means that 86% of
the increase was uncompensated for, or that overdiag-
nosis was 37%. When carcinoma in situ was included
overdiagnosis was 52% (table).
Meta-analysis
The total overdiagnosis of breast cancer in publicly
available mammography screening programmes
(includingcarcinomainsitu)was52%(95%confidence
interval 46% to 58%; fig 8). Heterogeneity was moder-
ate (I
2=59%).
DISCUSSION
In populations offered organised screening for breast
cancer, overdiagnosis (the detection of cancers that do
not cause death or symptoms) was 52%. Carcinoma in
situwasincludedinthisestimate,asitisgenerallytrea-
ted in the same way as invasive breast cancer
1224; the
overdiagnosis for invasive breast cancer only was 35%
(95% confidence interval 29% to 42%).
We took account of the increasing background inci-
dencebycomparingtheobservedratesofbreastcancer
with the expected rates for the last year of observation,
using projected incidence rates from prescreening
trends. Our assumption of a constant, linear increase
in the background incidence was supported by data
from age groups that were too young to be screened,
as agreement between projected and observed rates
was good (figs 2-5). Another indication that our
assumption was reasonable is that the incidence of
breast cancer only deviated from a linear increase
around the time of the introduction of screening. This
was the case in all included areas, even though screen-
ing was introduced at different times (from 1979 in
Manitoba to 1995 in Norway). It is therefore unlikely
that changes in risk factors or cohort effects could
explain the non-linear increases in incidence of breast
cancerthatoccurredwiththeintroductionofscreening.
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Fig 8 | Meta-analysis of overdiagnosis of breast cancer
(including carcinoma in situ) in publicly available
mammography screening programmes
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before organised screening was introduced,
13 but we
avoidedthisbiasbyestimatingtheprescreeningtrends
from periods when there were few diagnoses of carci-
noma in situ.
The trend after implementation of screening was
estimated under the assumption that screening leads
to a higher incidence level that increases at about the
same rate as the background incidence did before
screening.
25 Our data support this assumption (figs 2-
6).
As we have data on long follow-up it is unlikely that
theincreasingincidenceinthescreenedagegroupwill
be compensated for later on. Screening theory implies
that a compensatory drop would be apparent shortly
after women leave the screening programme and thus
after comparatively short follow-up.
25
Not all women in all areas passed from the screened
age group to the previously screened age group within
our observation period. In England and Wales, how-
ever, practically all women aged 65-74 would have
been offered screening previously at the end of our
observation period, but we did not find a compensa-
tory drop in incidence of breast cancer (fig 2).
Some authors use statistical models to adjust their
estimate of overdiagnosis for lead time (increased inci-
dence because of advancement of the time of
diagnosis).
26-30 This approach is problematic as all
models carry a high risk of bias
31 because they are
based on unverified assumptions, and as the choice of
variables is crucial—for example, high estimates of
lead time result in low estimates of overdiagnosis.
31
Estimates of lead time varied between 1.6 and 4 years
and even differed in articles by the same
authors.
1526272930
The recent decline in the use of hormone replace-
ment therapy after evidence that it causes breast
cancer
32 is a possible explanation for the reduction in
incidence observed in the United States from 2002, in
particular as such a decline did not occur in women
below50yearsofage.
33Wedidnot,however,seesimi-
lar declines in the countries we examined, and the
declining use of mammography screening in the Uni-
ted States has also been suggested as an explanation.
34
In Norway the effect of screening was separated
fromthatofhormonereplacementtherapyuse,asinci-
dence trends in regions with and without screening
could be compared at the same calendar times.
Although use of hormone replacement therapy is
likely to be similar, a noticeable increase occurred in
invasive cancer with the introduction of screening,
both in the Akershus, Oslo, Rogaland, and Hordaland
counties and in the remaining counties of Norway
(figs 6 and 7), and in the other regions we examined
(figs 2-4).
Conclusion
We estimated 52% overdiagnosis of breast cancer in a
population offered organised mammography screen-
ing—that is, one in three breast cancers is overdiag-
nosed.
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